Pink SheetUS Food and Drug Administration newcomer George Tidmarsh will have the unique challenge of learning to manage two agency centers at once, following Vinay Prasad’s short-lived tenure as Director of the
ScripThe departure of Vinay Prasad as US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director just three months after his appointment to the leadership role came as wel
Pink SheetVinay Prasad, the FDA’s newly-appointed Center for Biologics Evaluation and Research Director, was pushed out of his post July 29 after a wave of right-wing backlash over the past week that was critic
ScripA week after Sarepta Therapeutics agreed to stop shipping Elevidys (delandistrogene moxeparvovec) to ambulatory Duchenne muscular dystrophy (DMD) patients at the request of the US Food and Drug Admi